H1N1 PCR Diagnostic Tests to Use Local Biotech Company’s Oligos
// November 16th, 2009 // H1N1, PCR, diagnostic, oligo
Local Bay Area biotech company Biosearch Technologies has obtained a license from the CDC for the novel H1N1 Influenza signatures along with the Influenza A sub-typing panel signatures. This means that Biosearch Technologies’ oligonucleotides (oligos or primers) will be used in PCR diagnostic testing for detecting the H1N1 flu strain. The PCR diagnostic test has greater sensitivity, and therefore better accuracy, at detecting the pandemic strain (H1N1 type A) of the flu virus, than current rapid detection systems. Because of its sensitivity, the PCR test will also be able to detect if a person has had H1N1, if tested early enough (on or shortly after day 5).
